Revolution Medicines has been granted a patent for macrocyclic compounds that can inhibit Ras proteins, potentially leading to new treatments for cancers. The patent includes specific compounds and their pharmaceutical compositions, highlighting their potential in cancer therapy. GlobalData’s report on Revolution Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Revolution Medicines, Cancer treatment biomarkers was a key innovation area identified from patents. Revolution Medicines's grant share as of September 2023 was 14%. Grant share is based on the ratio of number of grants to total number of patents.
Inhibiting ras proteins for cancer treatment
A recently granted patent (Publication Number: US11739074B2) discloses a compound and a pharmaceutical composition comprising this compound. The compound, or a pharmaceutically acceptable salt thereof, falls within a specific group of compounds. The patent claims cover both the compound itself and its use in a pharmaceutical composition.
The first claim of the patent is for a compound or a pharmaceutically acceptable salt thereof. The compound belongs to a specific group of compounds, although the exact nature of this group is not specified in the provided information. The compound can be used as a standalone entity or in combination with a pharmaceutically acceptable salt. This claim establishes the scope of the patent and protects the compound from unauthorized use or production.
The second claim of the patent is for a pharmaceutical composition. This composition comprises the compound or a pharmaceutically acceptable salt thereof, as described in the first claim, and a pharmaceutically acceptable excipient. An excipient is an inactive substance that is added to a pharmaceutical formulation to aid in the delivery or administration of the active ingredient. The excipient used in this composition must be pharmaceutically acceptable, meaning it is safe and suitable for use in humans.
The combination of the compound and the excipient in the pharmaceutical composition allows for the effective delivery of the compound to the intended target in the body. This claim protects the specific formulation of the composition and ensures that it cannot be replicated or used without permission.
Overall, this granted patent (Publication Number: US11739074B2) covers a compound and a pharmaceutical composition comprising this compound. The compound belongs to a specific group of compounds, and the patent claims protect both the compound itself and its use in a pharmaceutical composition. The composition includes a pharmaceutically acceptable excipient, which aids in the delivery or administration of the compound. This patent provides legal protection for the compound and its formulation, preventing unauthorized use or production.
To know more about GlobalData’s detailed insights on Revolution Medicines, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
